PeriGen builds FDA-cleared, AI-driven perinatal monitoring software for hospital labor and delivery units, centered on PeriWatch Vigilance — the only commercially available continuous fetal heart rate interpretation system in the US. Founded in 1995 by Dr. Emily Hamilton and acquired by Halma plc in 2021, PeriGen now supports over 750,000 births annually across 500+ hospitals in the US and Canada.
Key features
- PeriWatch Vigilance: FDA-cleared fetal and maternal early warning system using supervised machine learning
- PeriWatch Surveillance: 510(k)-cleared centralized fetal surveillance and documentation platform
- Command Centers: facility or enterprise-level centralized monitoring hubs
- Vigilance Mobile App: iOS/Android access to early warning system and patient tracings
- LaborWatch: automated notifications and escalations for hospital leadership
- Quality Reports: performance and quality-measure reporting
- FDA-cleared multifactor labor progression algorithm
Strengths
- Only commercially available FDA-cleared continuous fetal heart rate interpretation algorithm in the US
- Recently expanded FDA clearance down to 32 weeks’ gestation (from 36 weeks)
- EMR- and central-monitor-agnostic — no “rip and replace” required
- 31+ years of clinical development history and published outcomes research
- Backed by Halma plc since 2021; won Halma Health Sector Company of the Year
Leave a Reply